FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:860-863 February 27, 2003 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Nathan, D. M. PubMed Citation

To the Editor: In their article on the dispute over the iron-chelating agent deferiprone (Oct. 24 issue),¹ Nathan and Weatherall focus on the ethical implications for the relationships among scientists, their institutions, and industry. Their article ignores recent evidence on the safety and efficacy of the drug^2,3,4,5 and does nothing to resolve the uncertainty that has made deferiprone unavailable to the majority of patients with thalassemia worldwide.

This very public controversy has generated fear, uncertainty, and doubt among such patients and their physicians, fomented mistrust among clinicians and researchers, and undermined patients' confidence in their doctors. Such doubts have been . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.